SeaStar Medical CEO to Present at Noble Capital Markets Conference
Event summary
- SeaStar Medical CEO Eric Schlorff to present at Noble Capital Markets Emerging Growth Virtual Equity Conference on February 5, 2026, at 11:30 AM ET.
- Presentation replay available from February 9, 2026, for 30 days.
- SeaStar Medical's QUELIMMUNE (SCD-PED) therapy is the only FDA-approved treatment for life-threatening acute kidney injury (AKI) in pediatric patients due to sepsis.
- Company's SCD therapy has received Breakthrough Device Designation for six therapeutic indications from the FDA.
- NEUTRALIZE-AKI pivotal trial ongoing for adult patients with AKI requiring continuous renal replacement therapy (CRRT).
The big picture
SeaStar Medical's participation in the Noble Capital Markets conference underscores its strategic focus on expanding its market presence in critical care therapies. The company's FDA-approved QUELIMMUNE therapy positions it uniquely in the treatment of life-threatening AKI in pediatric patients, while ongoing trials aim to extend its reach into the adult market. The Breakthrough Device Designation for multiple indications highlights the potential for faster regulatory pathways and favorable reimbursement dynamics, which could significantly impact its commercial strategy.
What we're watching
- Regulatory Progress
- Whether the Breakthrough Device Designation will accelerate approval timelines for SeaStar Medical's additional therapeutic indications.
- Clinical Trial Outcomes
- The pace at which the NEUTRALIZE-AKI pivotal trial for adult AKI patients will yield results and potential market expansion.
- Market Penetration
- How SeaStar Medical will leverage its FDA-approved status to increase adoption of QUELIMMUNE therapy in the ultra-rare pediatric AKI market.
Related topics